Janney Montgomery Scott LLC Buys 5,415 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Janney Montgomery Scott LLC increased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 17.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,047 shares of the company's stock after purchasing an additional 5,415 shares during the quarter. Janney Montgomery Scott LLC owned about 0.13% of Krystal Biotech worth $6,744,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Swiss National Bank increased its position in Krystal Biotech by 0.8% in the first quarter. Swiss National Bank now owns 36,200 shares of the company's stock worth $6,441,000 after purchasing an additional 300 shares during the period. Sei Investments Co. grew its position in shares of Krystal Biotech by 128.3% during the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company's stock worth $6,005,000 after buying an additional 18,968 shares during the period. Headlands Technologies LLC bought a new stake in shares of Krystal Biotech during the first quarter worth approximately $291,000. ProShare Advisors LLC lifted its holdings in Krystal Biotech by 9.0% in the first quarter. ProShare Advisors LLC now owns 5,865 shares of the company's stock valued at $1,044,000 after buying an additional 486 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its holdings in Krystal Biotech by 18.5% in the first quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company's stock valued at $1,300,000 after buying an additional 1,140 shares during the period. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Up 7.6 %

Shares of KRYS traded up $14.16 on Friday, hitting $199.61. The company's stock had a trading volume of 416,323 shares, compared to its average volume of 210,626. The firm's fifty day moving average price is $181.29 and its 200-day moving average price is $180.58. Krystal Biotech, Inc. has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The firm has a market capitalization of $5.74 billion, a price-to-earnings ratio of 112.77 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business's quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.67) earnings per share. As a group, equities analysts predict that Krystal Biotech, Inc. will post 2.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 14.10% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday. William Blair raised Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Chardan Capital upped their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a "buy" rating in a research note on Monday, August 5th. Finally, Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $197.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).